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Abstract
Patients with active untreated acromegaly show mild to moderate neurocognitive disorders that are associated to chronic
exposure to growth hormone (GH) and insulin-like growth factor (IGF-I) hypersecretion. However, it is unknown whether
these disorders improve after controlling GH/IGF-I hypersecretion. The aim of this study was to compare neurocognitive
functions of patients who successfully underwent GH-secreting adenoma transsphenoidal surgery (cured patients) with
patients with naive acromegaly. In addition, we wanted to determine the impact of different clinical and biochemical
variables on neurocognitive status in patients with active disease and after long-term cure. A battery of six standardized
neuropsychological tests assessed attention, memory and executive functioning. In addition, a quantitative electroen-
cephalography with Low-Resolution Electromagnetic Tomography (LORETA) solution was performed to obtain information
about the neurophysiological state of the patients. Neurocognitive data was compared to that of a healthy control group.
Multiple linear regression analysis was also conducted using clinical and hormonal parameters to obtain a set of
independent predictors of neurocognitive state before and after cure. Both groups of patients scored significantly poorer
than the healthy controls on memory tests, especially those assessing visual and verbal recall. Patients with cured
acromegaly did not obtain better cognitive measures than naı¨ve patients. Furthermore memory deficits were associated
with decreased beta activity in left medial temporal cortex in both groups of patients. Regression analysis showed longer
duration of untreated acromegaly was associated with more severe neurocognitive complications, regardless of the
diagnostic group, whereas GH levels at the time of assessment was related to neurocognitive outcome only in naı¨ve
patients. Longer duration of post-operative biochemical remission of acromegaly was associated with better neurocognitive
state. Overall, this data suggests that the effects of chronic exposure to GH/IGF-I hypersecretion could have long-term
effects on brain functions.
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Introduction
Acromegaly is a rare but severe hormonal disorder resulting
from aberrant GH (growth hormone) secretion and consequent
increase of IGF-I (insulin-like growth factor 1), most commonly
produced by pituitary adenomas. The development of this disease
is insidious, with a mean duration of 5–10 years from symptom
onset to diagnosis. Systemic complications are also common at the
time of diagnosis, including changes in the somatic, gastrointes-
tinal, cardiovascular, endocrine and metabolic systems, among
others [1,2].
Neurocognitive complications, including working memory and
long-term memory deficits, have been added to the long list of
complications associated with this disease [3–5]. Increasing
evidence suggests that the severity of these complications in
acromegaly patients is strongly correlated to circulating GH/IGF-
I levels and the duration of active disease, apparently independent
from psychiatric symptoms [3,4,6]. Recent magnetic resonance
imaging (MRI) studies have reported structural alterations in grey
and white brain matter (including the hippocampus) in acromegaly
patients [5,7]. Moreover, neurophysiological alterations have been
also described in active untreated (naı¨ve) patients. These patients
display decreased amplitude of the cognitive potential P300 under
the auditory oddball paradigm [3] as well as decreased alpha and
beta activity in specific cortical regions such as prefrontal cortex
(PFC) and medial temporal cortex (MTC) [4]. Altogether, these
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observations strongly suggest that prolonged GH/IGF-I excess
may have a negative effect on neural and cognitive function.
Nevertheless, few neurocognitive studies to date have been
conducted in cured acromegaly patients. The study of cured
acromegaly patients (patients in which GH/IGF-I levels have been
restored to normal concentrations) provides a unique opportunity
to examine the potential reversibility of alterations in brain
structure and function induced by GH and IGF-I excess. The first
therapeutic approach to active acromegaly is adenoma removal,
chiefly through transsphenoidal neurosurgery. However, despite
successful control of GH/IGF-I hypersecretion, this approach
does not always result in the complete relief of acromegaly-related
comorbidity. Severe cardiovascular complications and lesser
disorders, such as sleep apnea and incapacitating arthropathy,
are commonly observed in cured patients [8–10]. These compli-
cations contribute significantly to the decreased quality of life and
high rate of psychiatric disorders often associated with acromegaly
patients [11].
Our previous research had revealed that patients with active
untreated acromegaly show specific neurocognitive impairment
associated with increased GH and IGF-I levels [4]. In the present
study, we investigated the extent of neurocognitive impairment
after biochemical remission of acromegaly. To this end, we
assessed the neurophysiological and cognitive status of acromegaly
patients after surgical cure. To avoid potential confounding effects
of current adjuvant treatments for acromegaly (pharmacologically
and/or radiotherapy) in the neurocognitive assessment, our
analysis was restricted to patients cured by transsphenoidal surgery
alone. Based on our previous results, we tested the hypotheses that
cured acromegaly patients show better neurocognitive status than
patients with active disease, and that the persistence of neurocog-
nitive disorders after cure is linked to the duration of GH and IGF-
I hypersecretion. To test these hypotheses, we focused on a set of
clinical and biochemical variables that have previously shown to
correlate to neurocognitive status in acromegaly [3–5,7]. Howev-
er, previous work has been restricted uniquely to univariate
correlations. In the current work, we performed a more
comprehensive analysis from a multivariate analysis approach
that includes clinical, demographical and biochemical variables,
thus controlling for confounding effects, interactions and multi-
collinearity between variables.
We decided to focus on memory functions and their relationship
to PFC and MTP regions since previous studies have described
that these brain regions are functionally altered in active
acromegaly [4,12]. For comparison purposes, a group of patients
with naı¨ve (active untreated) acromegaly was included in the study.
Materials and Methods
Subjects
We obtained data on 102 patients diagnosed with acromegaly
between 1990 and 2010 from the databases of two University
hospitals in Andalusia, Spain. In all cases, acromegaly had been
diagnosed by the presence of relevant clinical signs: IGF-I above
the age-specific normal range (IGF-ISD) and failure to reduce GH
levels below 1 mg/liter during oral glucose tolerance tests (OGTT).
Patients with major psychiatric syndrome or neurological back-
ground, history of pituitary radiotherapy, untreated hypopituita-
rism, uncontrolled diabetes mellitus, or uncontrolled hypertension
were considered ineligible. Also excluded were patients that had
undergone transcranial surgery for pituitary adenoma removal
(Figure S1).
Patients with cured acromegaly were defined based on last
published consensus criteria (GH nadir below 0.4 mg/liter after a
post-operative 75-g OGTT and normal IGF-ISD level) [13]. The
patients included in this study had been cured of acromegaly
(according to the criteria described above) the preceding 6 months
(at a minimum) before the neurocognitive assessments. A total of
thirty patients met this criteria and were invited to participate in a
neurophysiological and cognitive assessment. Eight patients
declined (four noted incompatibility with work schedules, four
gave no explanation). Two patients did not complete the
assessment. The demographic and clinical characteristics of these
ten patients did not differ from those patients included in the final
sample.
Patients with naı¨ve acromegaly were also drawn from the
hospital databases. These newly diagnosed patients were on
waiting lists for transsphenoidal tumor resection. Exclusion criteria
included major psychiatric syndrome or neurological background,
uncontrolled diabetes mellitus, uncontrolled hypertension or
untreated hypopituitarism. Each patient from this group was
matched on gender and educational level to a patient in the cured
acromegaly group. Age matching was limited to a five-year age
difference. None of these patients had previously performed the
tests used in the current study.
Anthropometrical measures and blood sample collection for
standard biochemical analysis and hormonal parameters (GH,
IGF-I, PRL, LH, FSH, serum T4, TSH, 0900-h cortisol,
testosterone or estradiol) were performed under basal conditions,
between 8:00 am and 9:00 am, after an overnight fast (see
Supplementary information for hormonal assay description in
File S1).
Twenty demographically matched control healthy subjects were
included in the study. Exclusion criteria for this group included
any history of endocrine or neurological disease, and present or
previous substance abuse. Age did not differ among groups (see
Table S1 for demographic features of the groups). Subjects from
this sample were selected from a larger sample of voluntary
healthy subjects who served as individual controls in an
unpublished study on the prevalence of memory complaints in
patients with pituitary tumors. None of the control subjects had
previously performed the tests used in the current study. The study
protocol was approved by the Virgen del Rocio University
Hospital Medical Ethics Committee (report number: A08011074).
Written informed consent was obtained from all participants.
Cognitive Measures
To assess cognitive functions, we applied six standardized
neuropsychological tests, selected on the basis of proven sensitivity
to cognitive deficits in neuroendocrine disease [4,12]. These tests
were classified and subdivided into four cognitive domains:
attention, executive functioning, working memory and delayed
memory recall (verbal and visual) [14]. The tests included two
computerized versions of the Letter Cancellation Tasks, the Tower
of Hanoi and the Stroop Color-Word Test, the Trail-Making Test
(B), Luria’s Memory Words Test-Revisited (LMW-R), the
Complex Figure Test (CFT), and the Digit Span Test (see File
S1 for more details).
Neurophysiological Measures
Resting-state brain function was assessed using electroenceph-
alography (EEG) data from a 32-channel digital EEG recorder
(linked-ears reference, bandwidth [0.1–100 Hz], sampling fre-
quency = 256 Hz), with electrode placement in accordance with
the 10–10 system [15]. Each participant underwent a three-minute
resting state EEG recording (eyes closed). Raw data was processed
and filtered offline using EEGLAB [16]. Power spectral analysis
(1–40 Hz, 1 Hz resolution) was conducted on artifact-free EEG
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segments using the Fast Fourier Transform (FFT). We then
averaged data across frequency band and scalp location to obtain
measures for frontal, central-temporal and parietal-occipital
electrode placement.
We also applied Low-Resolution Electromagnetic Tomography
(LORETA) solutions to locate the source of EEG activity from the
scalp-recorded data [17]. LORETA is a functional imaging
technique that models EEG sources into 3D distributions [18],
providing a linear solution to the inverse EEG problem. This
technique uses a three-shell spherical head model that includes
scalp, skull and brain compartments. The latter is restricted to the
cortical gray matter and hippocampus of a head model co-
registered to the Talairach probability atlas, digitized at the Brain
Imaging Center of the Montreal Neurological Institute [19]. This
compartment includes 2,394 voxels (7 mm resolution), each
containing an equivalent current dipole. We obtained LORETA
values for the following frequency bands: delta (1–3 Hz), theta (4–
7 Hz), alpha (8–12 Hz), beta 1 (13–18 Hz), beta 2 (19–21 Hz),
beta 3 (22–30 Hz), and gamma (31–40 Hz). We performed region
of interest (ROI) analysis on the PFC (Brodmann areas 8 to 11 and
44 to 47) [20] and the MTC (Brodmann areas 27, 28, 34 to 36,
including the fusiform gyrus) [21].
Quality of Life (QoL) Measure
A self-administered questionnaire was used to assess the impact
of acromegaly on patients’ QoL. The Acromegaly Quality of Life
Questionnaire (AcroQoL), specifically developed for QoL assess-
ment in patients with acromegaly [22], was used. This question-
naire assesses both the physical and psychological aspects of the
disease. AcroQol was not administered to healthy subjects.
Statistical Analysis
The Fisher exact probability test was used to evaluate the
association between categorical variables. For general cognitive
and memory tests, one-way and repeated measures ANOVA/
ANCOVA tests were chosen, respectively. In these analyses,
covariates included number of comorbidities and QoL status. The
familywise error rate corrected p-value was estimated using 5,000
permutations. A Bonferroni correction was used for pairwise post
hoc comparisons.
The EEG power spectral analysis (from 1–40 Hz) was grouped
into classic frequency bands. We used non-parametric statistical
mapping to analyze the LORETA results. After applying subject-
wise normalization, we conducted group comparisons using voxel-
by-voxel permutation testing. To assess statistical differences in our
ROIs, exact randomization probabilities (5,000 randomizations),
corrected for multiple comparisons, were calculated to test cluster
size. To study possible relationships between clinical parameters
and neurocognitive variables, we carried out group level analyses
using a random-effects ordinary least squares model that included
the following predictors: 1) constant (overall mean), 2) patient
group (cured, naı¨ve, i.e. effects coding 1 or 21), 3) GH levels, 4)
GH levels6diagnostic group, 5) duration of untreated disease, 6)
duration of untreated disease6diagnostic group. Additional
covariates included age at diagnosis, Qol status, prolactin levels,
hypertension, diabetes and hypopituitarism. The variable ‘dura-
tion of untreated disease’ (the time the patient was exposed to
increased IGF-I or GH without treatment) was estimated on each
patient as described elsewhere [7]. In addition, the impact of the
duration of the biochemical remission (defined as the period
between GH/IGF-I normalization and neurocognitive testing in
treated patients) on neurocognitive functions was assessed in a
linear regression analysis. IGF-I levels were not entered in this
analysis to avoid multicollinearity with GH levels. In order to
obtain predictive capacity of clinical variables on abnormal results,
dependent variables were transformed into Z-scores using data
from healthy subjects. Given that residuals of the regression
equations were not normally distributed, tests of significance of the
regression coefficients were performed using permutations of the
residuals of the model.
After applying an exploratory analysis using p = 0.05, sufficient
power (b= 0.8) was obtained to detect an effect size as large as
f = 0.25, corresponding to an explained variance of 6%. A more
restrictive value of p = 0.005 allowed the detection of an effect size
as large as f = 0.31 with enough power, corresponding to an
explained variance of 9%. Even though this level of power seems
adequate to identify medium to large [23] differences among
groups, the sample size included in this study should be considered
as small compared to standard studies. Both the low incidence/
prevalence of acromegaly (incidence 3–4 cases per million/year,
prevalence 40–60 cases per million) and the strictness of the
inclusion criteria precluded us from obtaining a larger sample size.
Even though this could be seen as a limitation of the study, it
allowed us to perform a very exhaustive clinical assessment of
patients (compliance mainly), otherwise unfeasible in larger
samples.
GPower 3 served for the analysis of power (http://www.psycho.
uni-duesseldorf.de/aap/projects/gpower/), R 2.13.0 (http://
www.r-project.org/) and package ‘lmPerm’ (available in the
CRAN repository (http://cran.r-project.org/web/packages/
lmPerm/) served for all the other statistical analyses.
Results
Patient Characteristics
Patients’ clinical characteristics are shown in Table 1. No
differences in the age at acromegaly diagnosis between groups
were found (p = 0.748). As expected, cured patients showed normal
GH and IGF-I values at assessment. Conversely, all naı¨ve
acromegaly patients showed IGF-I levels above the normal age-
specific range (.3 SD) and GH hypersecretion (F = 17.48,
p,0.001), as compared to cured patients). We should note that
the hormonal analysis showed higher mean PRL serum levels in
naı¨ve patients (F = 4.79, p = 0.038), but this was due to the
inclusion of patients with mixed GH/PRL secreting adenoma. As
average, comorbidities were fewer in cured acromegaly patients as
compared to naı¨ve patients (F = 11.46, p = 0.001), as previously
reported [1,24]. Nevertheless, no significant differences in number
of patients with hypertension (p = 0.191), diabetes (p = 0.661) or
hypopituitarism (p = 0.301) between groups were found. Similarly,
no differences in tumor characteristics (size and extension) (all p-
values .0.647) and mean duration of untreated disease (p = 0.983)
were found between patient groups.
Cognitive Function after Cure of Acromegaly
Means and standard deviations of the scores of neuropsycho-
logical tests are presented in Table 2. Overall, acromegaly patients
displayed poorer working memory performance compared to
healthy controls. Main effect of Group was significant in the
backward task of the Digit Span Test (F = 7.01, p-perm = 0.008).
This effect remained significant after adjusting by covariates (p-
perm = 0.046). Post hoc analysis revealed that naı¨ve patients
performed worse in the backward task of the Digit Span test than
healthy subjects (p,0.05, Bonferroni corrected), while naı¨ve and
cured patients did not differ significantly in this test (p = 0.220).
Differences in several indexes of the LMW-R that accounts for
learning capability and accuracy, such as the True Recall Index
(F = 3.23, p = 0.034; cured vs. healthy subjects post hoc compar-
Neurocognitive Function after Cure of Acromegaly
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ison, p,0.05, Bonferroni corrected) and the Confabulation Index
(F = 4.37, p = 0.034, naı¨ve vs. healthy subjects post hoc compar-
ison, p,0.01, Bonferroni corrected) were also observed.
Patients also performed worse than healthy controls in tests
assessing delayed memory recall. Performance of cured patients
was also impaired in these tests, showing levels similar to those
observed in naı¨ve patients. More specifically, our analysis revealed
that both cured and naı¨ve patients performed worse in the test
assessing delayed verbal recall (LMW-R) than healthy subjects
(p,0.0001 in both comparisons, Bonferroni corrected) while
patients’ performance in the immediate recall condition was
similar to that of healthy subjects (p.0.102). In addition, patients
performed worse in the memory condition of the Complex Figure
Test (F of the interaction = 4.78, p = 0.003; post hoc pairwise
comparisons: naı¨ve vs. healthy, p,0.0001, cured vs. healthy,
p,0.05, naı¨ve vs. cured, p,0.10, Bonferroni corrected), which
assesses visual recall while no differences among the three groups
were observed in the copy condition.
We performed multiple linear regression analysis, as described
above, on delayed memory recall tests (CFT and LMW-R). In
CFT, the regression analysis (adjusted R2 = 0.315, p = 0. 0.007)
revealed that duration of untreated acromegaly was independently
associated with poor memory performance in both naı¨ve and
cured patients (b=21.095, t =22.082, p-perm = 0.004). Acro-
Table 1. Characteristics of the patient samples included in the study.
Cured acromegaly (N=20) Naı¨ve acromegaly (N=20)
Age at diagnosis, mean (SD) 46.40 (11.08) 48.50 (10.25)
GH (mg/liter), mean (SD) 0.40 (0.51) 16.32 (14.72)
IGF-I (mg/liter), mean (SD) 179.63 (104.70) 1022.28 (507.16)
IGF-ISD, mean (SD) 0.37 (1.83) 16.29 (8.39)
Prolactin (mg/liter), mean (SD) 7.22 (3.41) 25.03 (30.27)
Surgery, n (% of patients)
Transphenoidal 20 (100) 0
No 0 20 (100)
Comorbidities, n (% of patients)
Myocardiopathy 2 (10) 2 (10)
Hypertensiona 5 (25) 10 (50)
Arthralgia 2 (10) 2 (10)
Carpal tunnel syndrome 1 (5) 6 (30)
Diabetes mellitusb 2 (10) 4 (20)
Sleep apnea 1 (5) 5 (25)
Malignancy 1c (5) 0
Dyslipidemia 3 (15) 4 (20)
Gallstones 1 (5) 4 (20)
Hypopituitarism (any axis) 8 (40) 4 (20)
ACTH 2 (10) 2 (10)
TSH 5 (25) 2 (10)
FSH/LH 5 (25) 1 (5)
Depression 6 (30) 3 (15)
Tumor characteristics, n (% of patients)
Macroadenoma 13 (65) 17 (85)
Microadenoma 7 (35) 3 (15)
Suprasellar extension 4 (20) 4 (20)
Cavernous sinus extension 7 (35) 7 (35)
Sphenoid sinus extension 0 2 (10)
GH secreting adenoma 14 (70) n/a
Mixed GH/PRL secreting adenoma 6 (30) n/a
Duration of untreated disease, mean months (SD) 59.65 (55.79) 59.32 (40.88)
Duration of biochemical remission mean months (SD) 95.73 (59.01) n/a
AcroQoL scored 31.85 (25.28) 42.82 (24.40)
aTreatment in the cured acromegaly group (n): angiotensin-converting enzyme inhibitors (4); angiotensin II type 1 receptor blockers (1). Treatment in the naı¨ve
acromegaly group: angiotensin-converting enzyme inhibitors (6); calcium channel blocker (3); angiotensin II type 1 receptor blockers (1).
bAll the patients were treated with metformin for diabetes. Only one patient (cured acromegaly) required additional insulin treatment.
cColorectal cancer.
dThe higher the score in this questionnaire, the worse self-perceived QoL is.
doi:10.1371/journal.pone.0060041.t001
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megaly patients (both naı¨ve and cured) with longer exposure to
untreated GH/IGF-I excess performed worse in the CFT delayed
recall test. The naı¨ve group also displayed a significant negative
relationship between GH levels and performance in CFT delayed
recall (b=21.657, t =22.565, p-perm = 0.011) (Fig. 1A). How-
ever, a trend towards worse visual memory performance in both
naı¨ve and cured patients was observed when hypopituitarism
entered the analysis (b=20.066, t =21.861, p-perm = 0.074),
indicating that hypopituitarism was associated with lower scores in
the CFT test. Furthermore, duration of biochemical remission was
positively associated with performance on the CFT test (p-
perm = 0.021) (Fig. 1B). The regression analysis did not provide
a reliable predictor for the LMW-R test (delayed verbal recall)
(p = 0.151; data not shown).
Neurophysiological Function after Cure of Acromegaly
Significant differences in EEG power spectra recorded at
parieto-occipital locations were found between the three groups.
More specifically, differences in parieto-occipital alpha (F = 7.487,
p,0.0001), beta 2 (F = 4.415, p = 0.015), beta 3 (F = 3.805,
p = 0.028), and gamma (F = 3.102, p = 0.015) were found between
the three groups. Post hoc comparisons revealed decreased alpha
and beta 2 power (sqmicroV) in both cured and naı¨ve patients
compared to healthy subjects (all p,.05). Interestingly, no
significant differences were found in faster frequency bands
between cured patients and healthy subjects, whereas naı¨ve
patients displayed significant power decrease in beta 3 (p,0.02)
and gamma (p = 0.045) bands compared to healthy controls
(Fig. 2A).
LORETA analysis of the whole solution space identified two
cortical areas with the highest reliable effects. Maximal statistical
differences were found in the right dorsolateral PFC, in the 22–
40 Hz range (F = 3.785, p = 0.012), and in the left parahippocam-
pal cortex, in the 8–18 Hz range (F = 4.604, p = 0.006) (Fig. 2B).
ROI analysis (Fig. 2C) supported these findings, with naı¨ve and
cured patients displaying decreased beta 2 and 3 activity in the left
MTC. In addition, decreased alpha activity in the right PFC was
found in naı¨ve patients compared to healthy subjects. LORETA
source analysis for beta 1 also showed decreased right PFC activity
in naı¨ve patients compared to cured patients.
In terms of Cohen [23], weak to moderate correlations were
found between LORETA ROI activity and memory performance,
particularly between CFT performance and left MTC beta 3
activity, for both patient groups. A significant correlation was also
found between CFT and right PFC beta 1 activity in the naı¨ve
group (Table 3).
Multiple regression analysis of LORETA activity (beta 2:
adjusted R2 = 0.313, p,0.0001; beta 3: adjusted R2 = 0.494,
p,0.0001) revealed significant negative relationships between
LORETA beta 2 (b=20.009, t =22.039, p-perm = 0.049) and
beta 3 (b=20.014, t =22.710, p-perm = 0.014) activities in the
left MTC and the duration of untreated disease, for both cured
Table 2. Neuropsychological test results for acromegaly groups and healthy controls.
Cured patients Naı¨ve patients Healthy subjects
Attention
Simple attention test, RT (sec.) 0.488 (0.06) 0.467 (0.06) 0.449 (0.06)
Conditional attention test, RT (sec.) 0.387 (0.13) 0.399 (0.05) 0.403 (0.08)
Trail Making Test A, time (sec.) 56 (30.04) 61.1 (27.92) 39.5 (9.26)
Executive functioning
Trail Making Test B, time (sec.) 135 (77.24) 186.4 (93.48) 89.6 (25.71)
Stroop Color-Word Test, RT (sec.) 1.62 (0.39) 1.64 (0.59) 1.44 (0.31)
Tower of Hanoi test, total time (sec.) 177 (144.32) 246 (177.70) 154 (112.19)
Memory
Digit Span Test (forward) 7.60 (1.95) 6.94 (1.60) 8.17 (1.11)
Digit Span Test (backward) 5.33 (1.50) 4.13 (1.53)a,d 6.17 (1.26)
LMW-R
True Recall Index 8.29 (1.01)a,e 8.36 (0.83) 8.98 (0.50)
Confabulation Index 4.56 (3.43) 5.93 (3.44)b,e 2.43 (1.57)
Delayed recall 6.94 (1.09)c,f 7.40 (1.45)c,f 9.25 (0.90)
Complex Figure Test
Copy condition 32.5 (4.31) 32.8 (5.81) 35.2 (1.19)
Memory condition 20.3 (5.78)a,g 15.3 (6.87)c,g 26 (4.22)
Means (SD) are shown.
ap,0.05, vs. healthy subjects comparison.
bp,0.01, vs. healthy subjects comparison.
cp,0.001, vs. healthy subjects comparison.
dMedian score in normative data = -1.77.
eThese indexes do not have normative data available.
fMedian score in normative data: cured patients =21.68 (35% of patients scored below 21.5 SD); naı¨ve patients =22.21 (50% of patients scored below 21.5 SD);
healthy subjects = 0.14 (no patient scored below 21.5 SD).
gMedian percentile with test’s normative data: cured patients = 12.5 (40% of patients below 10th percentile); naı¨ve patients = 4 (70% of patients below 10th percentile);
healthy subjects = 50 (no patient below 10th percentile).
Note: LMW-R = Luria’s Memory Words Test-Revised.
doi:10.1371/journal.pone.0060041.t002
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and naı¨ve groups. In other words, longer exposure to high levels of
GH and IGF-I was associated with weaker LORETA activity in
left middle temporal areas (Fig. 3A).
Neither age at diagnosis, hypertension or diabetes was
associated with MTC LORETA activity (p-perm.0.12). Patients
with hypopituitarism, regardless of the patient group, showed a
trend of having less LORETA activity in left MTC beta 2 and beta
3 (p-perm = 0.060 and 0.051, respectively). We also observed a
negative relationship between right PFC LORETA beta 1 activity
and GH levels in patients with naı¨ve acromegaly (b=20.156,
t =23.428, p-perm = 0.002), but not in cured patients (Fig. 3B). In
addition, duration of biochemical remission correlated positively
with right PFC beta 1 (p-perm ,0.0001) and left MTC beta 2
activities (p-perm = 0.001). Duration of remission was not signif-
icantly associated with any other ROI’s activity (p-perm .0.07).
Discussion
Contrary to our expectations, cured acromegaly patients
displayed specific memory deficits. Thus, our cognitive assessments
do not indicate full recovery from neurocognitive impairment after
cure of acromegaly, at least in patients with short-term biochem-
ical remission.
Accumulating evidence indicates that neurocognitive impair-
ment should be added to the list of complications associated with
acromegaly. Sievers et al. [5] reported that almost 70% of
acromegaly patients of their cohort performed below normal
levels in at least one cognitive test (memory, attention or executive
functions). Our results showed a lower prevalence of cognitive
deficits in acromegaly patients, but it is important to note that the
Sievers study included a heterogeneous sample group comprised of
patients with a history of radiotherapy (25%) or uncontrolled
disease (40%), which may explain the discrepancy between these
results. Our study also shows that patients with surgically cured
acromegaly display significant power and topographical EEG
alterations similar to those registered in naı¨ve patients. Using EEG
power spectra and intracortical tomography (LORETA), we found
that cured patients showed lower alpha and beta cortical activity in
left medial temporal cortex than the healthy group. These
differences in the LORETA analysis correlated positively with
the performance on the memory condition of the CFT, which
assesses visuospatial memory. The delayed recall condition of the
CFT is perhaps the most widely used neuropsychological test in
clinical settings to study the non-verbal aspect of memory [25].
This test has been classically used to assess memory functions that
rely on structures located in the right hemisphere, especially
hippocampus and associated regions in the medial temporal lobe
[26,27]. In our study, our analysis revealed a significant association
between performance on this test and left MTC activity suggesting
that this area might have an important role on non-verbal memory
processes. In agreement with this hypothesis, neuropsychological
studies have found that patients with left hemisphere stroke also
show impairment in this test [28], whereas other studies have not
found an association between performance on CFT and right
temporal lobe lesions [29]. A potential explanation for these
findings is that verbal encoding (which relies more on the left
hemisphere) might be necessary for the patient to storage a large
number of different geometrical figures and their positions [30].
Our analysis expands and refines previous results (including our
own) by identifying a number of variables that independently
predict the presence of neurocognitive impairment in acromegaly,
even after cure. Lower memory scores in both patient groups were
associated with longer duration of untreated disease (i.e., longer
exposure to high levels of GH and IGF-I). The fact that prolonged
exposure was related to neurocognitive outcome in both cured and
naı¨ve acromegaly is not entirely surprising. Longer exposure to
GH/IGF-I hypersecretion has been linked to an increased
prevalence of other systemic complications, namely cardiovascular
or joint disorder, which often persist after cure of the disease
[1,24]. Interestingly, previous studies have linked the duration of
untreated active disease to volumetric changes in global brain
volume as well as left and right hippocampus in acromegaly
patients [5,7].
The regression analysis also revealed that GH levels predicted
PFC beta activity in naı¨ve acromegaly but not in cured patients.
Noteworthy, this area showed decreased LORETA activity as
compared to both cured and healthy subjects. These observations
suggest that neurocognitive deficits are linked to hypersecreted
GH levels, thus providing a possible explanation for the slightly
better neurocognitive state (especially in learning processes) of
cured patients observed in our study. This is also supported by the
fact that a significant association between right PFC beta activity
and CFT performance was found only in naı¨ve patients. This data
Figure 1. Relationship between clinical predictors obtained from multivariate regression analysis and cognitive data. (A) longer
duration of untreated acromegaly (in months) is independently associated with worse visual memory performance. Higher GH levels are
independently associated with worse visual memory recall in patients with naı¨ve acromegaly, but not in cured patients. (B) shorter biochemical
remission is positively associated with worse visual memory recall. CFT, Complex Figure Test. Partial R2 were calculated controlling for the other
variables in the model.
doi:10.1371/journal.pone.0060041.g001
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suggests that hypoactivity in PFC might contribute to memory
deficits in naı¨ve acromegaly patients.
Based on previous results [5], we expected that patients with
acromegaly would show deficits in executive functions, especially
in those patients with decreased PFC LORETA activity. However,
we could not detect statistically significant differences among the
different groups. This could be due to the sample size of our study
that was not adequate to detect subtle differences (due to the strict
exclusion criteria used) in cognitive functions linked to the PFC.
This is also supported by the power analysis we performed, which
indicated that only moderate to large effects could be detected.
Additional studies with larger sample sizes are necessary to
conclusively demonstrate whether non-memory related cognitive
domains are affected in acromegaly patients.
Another important result from our study is that longer
biochemical remission of acromegaly is associated to better
neurocognitive status. This result raises the question whether
neurocognitive impairment might improve after long-term remis-
sion. In agreement with this hypothesis, another study reported
low prevalence of memory deficits in a cohort of acromegaly
patients with longer duration of remission [6] (mean duration of
remission of 13.161.0 years compared to 8.3561.17 years in our
study). Likewise, a recent study on patients with median
biochemical remission of 8 years showed similar results to ours
[31]. Prospective studies with longer follow up are needed to
conclusively prove full recovery from neurocognitive impairment
in cured acromegaly patients.
The mechanisms by which increased GH levels might alter
brain functions remain purely speculative but it is important to
note that GH and IGF-I can cross the brain-blood barrier [25]
and thus, these factors might directly affect brain structures
relevant to cognitive functions. In this regard, increased hippo-
campal volume has been described in acromegaly patients
although it is unclear whether this is due to increased neurogenesis
in hippocampus [5,7]. Interestingly, in animal studies increased
GH/IGF-I signaling promotes neurogenesis in the dentate gyrus
[32–34]. However, other studies have shown that brain over-
growth mediated by GH/IGF-I hypersecretion is due to increased
gliogenesis and glial activity (increased myelin production) rather
than increased neurogenesis [35,36]. Further studies are required
to determine the neurobiological basis of the alterations in brain
structure and function observed in acromegaly patients. Interest-
ingly, both decreased and excess GH and IGF-I levels have been
linked to alterations in cognitive functions. Falleti et al. [37]
reported moderate impairment in memory and executive func-
tions in patients with adult-onset GH deficiency. However,
whether excessive and defective GH secretion cause these deficits
through common mechanisms remains to be determined. What-
soever the pathophysiological commonalities between GH/IGF-I
excess and deficiency might be, cumulative data indicate that GH/
IGF-I circulating levels must be kept within a very specific range
for proper brain function.
We acknowledge that our data suggests but does not prove a
causal relationship between GH/IGF-I overproduction and
neurocognitive impairment in acromegaly. As in other chronic
diseases, patients with acromegaly may suffer from neurocognitive
disturbances as a consequence of more general factors (e.g.
decreased QoL or psychiatric disorders). Other cross-sectional
studies have tried to address this issue by including patients with
non-functioning pituitary adenoma (NFPA) as a comparison
group, but controversial results have been obtained [6,31].
Specific comorbidities associated to acromegaly might also
potentially have an impact in the neurocognitive impairment
observed in our study. For example, hypertension, diabetes and
hypopituitarism may, per se, alter brain structure and function. Our
study found that these variables had little impact on neurocogni-
tive functions. Unfortunately, MRI/CT scans of brain parenchy-
ma were not available in most of the patients in our study.
However, previous work using magnetic resonance imaging failed
to find a relationship between white matter lesions (likely due to
Figure 2. Neurophysiological results of patients with acromegaly. (A) Power spectra differences (frequency range: 1–40 Hz) among patient
groups and healthy controls. Decreased EEG power was observed in fast bands (alpha and beta) for both patient groups. Note the decreased power
in patients with acromegaly at peak alpha frequency, 10 Hz. (B) LORETA comparisons between acromegaly patients and healthy controls. Upper
panel: comparison between cured patients and healthy subjects. Highest significant LORETA differences were found in left medial temporal cortex in
beta 2 band (4 significant neighboring voxels, 1.37 cm3, p,0.04) and beta 3 band (15 significant neighboring voxels, 5.14 cm3, p,0.007). Cured
patients showed significantly lower LORETA activity than healthy subjects in cortical areas shown in blue. Lower panel: comparison between naı¨ve
patients and healthy subjects. Highest significant LORETA differences were found in left medial temporal cortex in beta 2 band (8 significant
neighboring voxels, 2.74 cm3, p,0.012) and beta 3 band (30 significant neighboring voxels, 10.29 cm3, p,0.005) and in right dorsolateral PFC in
alpha (8 significant neighboring voxels, 2.74 cm3, p,0.012) and beta 1 (28 significant neighboring voxels, 9.604 cm3, p,0.006) bands. Naı¨ve patients
showed significantly lower LORETA activity than healthy subjects in cortical areas shown in blue. Scales show maximal t value and maximal significant
t value (p,0.05, corrected for multiple comparisons). (C) ROI analysis comparisons among groups. ROI LORETA activity in acromegaly patients is
reduced as compared to healthy subjects. *p,0.05; **p,0.01, corrected for multiple comparisons.
doi:10.1371/journal.pone.0060041.g002
Table 3. Correlation coefficients (Pearson’s r), with associated p values (calculated after 5,000 randomizations) for the correlation
analysis between LORETA ROI activity and performance in delayed recall tests.
Cured (N=20) Naı¨ve (N=20) Overall
LMW-R CFT LMW-R CFT LMW-R CFT
rPFC alpha –.33(.140) 2.02 (.940) .39 (.095) .36 (.124) .19 (.240) .11 (.497)
rPFC beta 1 2.34 (.139) .36 (.129) .23 (.351) .67 (.002) 2.01 (.928) .27 (.102)
lMTC beta 2 .26 (.275) .43 (.059) .09 (.696) .23 (.351) .11 (.497) .24 (.147)
lMTC beta 3 .33 (.160) .62 (.004) .05 (.984) .69 (.001) .05 (.746) .63 (,.001)
Significant associations shown in bold.
Note: LMW-R = Luria’s Memory Words Test-Revised; CFT =Complex Figure Test.
doi:10.1371/journal.pone.0060041.t003
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vascular risk factors) and cognitive impairment, suggesting that
cognitive impairment is not mainly due to neurovascular
pathology in acromegaly [5].
In conclusion, our study reveals that patients after cure of
acromegaly show specific memory deficits and EEG alterations.
Our results indicate that treatment outcome (surgically cured
acromegaly) did not include full recovery from neurocognitive
complications. Neurocognitive complications after post-operative
biochemical remission of acromegaly are related to prolonged
GH/IGF-I hypersecretion before surgery, although the underlying
mechanisms remain unknown. Finally, our data show that patients
with longer duration of remission display better neurocognitive
functions. In the realm of clinical endocrinology, these results
should be considered for the long-term prognosis of neurocogni-
tive complications of patients with acromegaly.
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